On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

A novel, noninvasive brain stimulation approach—known as transcranial temporal interference stimulation (TIs)—may offer a new ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) ...

The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode identifier) for people with Parkinson's disease, Medtronic announced Monday. Like ...

A new study led by Bucknell University Professor Karlo Malaga, biomedical engineering, has identified key insights into optimizing deep brain stimulation (DBS) for Parkinson's disease patients.

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease For 30 years, people with Parkinson's disease ...

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson's ...